RGNX

Regenxbio Inc.

Price

$12.02

return (12m)

49.69%

p/e

-2.85

p/bv

7.80

DIVIDEND YIELD

0.00%

RGNX price

Regenxbio

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment RGNX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

15.69%

3 months

78.07%

1 year

49.69%

2 years

-3.69%

5 years

-59.43%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals RGNX

Valuation

P/E

-2.85

Sector -4.38

Industry -4.38

P/BV

7.80

Sector 2.02

Industry 2.02

P/Revenue (PSR)

3.21

Sector -4.40

Industry -4.40

EV/EBITDA

13.26

Sector -263.09

Industry -263.09

EV/EBIT

14.90

Sector -702.90

Industry -702.90

P/EBITDA

-4.02

Sector -4.39

Industry -4.39

P/EBIT

-3.62

Sector -4.73

Industry -4.73

P/Total Assets

1.45

Sector 1.49

Industry 1.49

P/Net Current Assets

-7.12

Sector -11.70

Industry -11.70

P/Working Capital

3.65

Sector -3.19

Industry -3.19

EPS

-3.71

Sector -2.14

Industry -2.14

BVPS

1.35

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

86.38%

Sector 36.74%

Industry 36.74%

EBITDA Margin

31.72%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

28.24%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-94.08%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.28

Sector 0.03

Industry 0.03

Profitability

ROE

-273.69%

Sector -65.14%

Industry -65.14%

ROA

-50.81%

Sector -65.53%

Industry -65.53%

ROIC

52.23%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

2.86

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-3.08

Sector -6.07

Industry -6.07

Net Debt / EBIT

-3.46

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.47

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.19

Sector 0.41

Industry 0.41

Liabilities/Assets

0.81

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-17.99%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals RGNX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
RGNX Regenxbio Inc.	$12.02	38.00%	0.00%	-2.85	7.80	-273.69%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

RGNX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Regenxbio

Regenxbio Inc.

Average Investor10 user rating

4.0 (2 people)

United States

18 years

Founded: 2008

2015

Time since IPO - 11 years

257

Employees

Regenxbio Inc. (United States) is listed on the Nasdaq and has a market capitalization of $559.95 million, with shareholders equity totaling $71.77 million.

The company employs approximately 257 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Regenxbio Inc. reported $174.48 million in revenue, generating net income of $-196.43 million.

Key financial metrics include a P/E ratio of -2.85, a price-to-book (P/B) ratio of 7.80, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker RGNX.

Market cap

$559.95 million

Net worth

$71.77 million

$71,770,000.00

Assets

$386.62 million

$386,620,000.00

Total Shares Outstanding

53.00 million

53,000,000

Average Daily Trading Volume

$2.10 million

$2,102,993.26

Sector

Health Care

Industry

Biotechnology

RGNX

RGNX revenue and profits

Financial Results RGNX

DRAG THE FRAME TO SEE MORE DATA

RGNX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Regenxbio (RGNX) today?

A cotação de Regenxbio (RGNX) hoje está em US$ 12.02, com uma variação de 49.69% em relação ao último ano. A cotação de Regenxbio (RGNX) iniciou o ano negociando na casa dos US$ 14.40 e hoje está em US$ 12.02. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Regenxbio (RGNX) e dados de ações do Ibovespa e mercados internacionais.

Quando Regenxbio (RGNX) paga dividendos?

Regenxbio (RGNX) não distribuiu dividendos no último ano.

Is Regenxbio (RGNX) a good investment?

Atualmente, Regenxbio (RGNX) está cotada a US$ 12.02, com um P/L de -2.85, representando um desvio de -295% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 49.69 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 49.69%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Regenxbio (RGNX) stock?

Investir em ações de Regenxbio (RGNX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Regenxbio (RGNX) yield today?

A rentabilidade de Regenxbio (RGNX) foi de 15.69% no último mês, 49.69% no último ano e -59.43% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Regenxbio (RGNX) hoje, o investimento total seria de US$ 1,202.00, com base na cotação atual de US$ 12.02.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 1,799.27
Em 5 anos: US$ 487.65
Em 10 anos: US$ 1,202.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

RGNX

Regenxbio Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment RGNX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING RGNX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Regenxbio

Regenxbio Inc.

United States

18 years

2015

257

PROFIT X PRICE RGNX

Financial Results RGNX

RGNX cash flow

Asset, Revenue and Profit Growth - RGNX

RGNX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions